Our pipeline – Circio

2H 2023In vivo proof-of-concept data

Solid tumors circAde

circVec
circRNA vector

2H 2023In vivo proof-of-concept data

Infectious disease, circVac

2H 2023Target screening and selection

Rare disease

ONCOS-102
mRNA vector¹

TBD 2023-24
Initiation of phase 2 trial (USA)

PD-1 Resistant Melanoma Re-challenge combination w/aPD-1 & CTLA-4

Mutant KRAS¹

1H 2023
First patient dosed (USA & EU)

Pancreatic cancer & Multiple Myeloma TG01/QS-21 +/- anti-PD-1

ONCOS

Cancer Indication: Solid tumors circAde
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data

Discovery

In vivo PoC

Phase 1

Phase 2

Phase 3 / pivotal

Cancer Indication: Infectious disease, circVac
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data

Discovery

In vivo PoC

Phase 1

Phase 2

Phase 3 / pivotal

Cancer Indication: Rare disease
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
Target screening and selection

Discovery

In vivo PoC

Phase 1

Phase 2

Phase 3 / pivotal

Cancer Indication: PD-1 Resistant Melanoma
Combination with: Re-challenge combination w/aPD-1 & CTLA-4
Product candidate: ONCOS-102 mRNA vector¹
Next expected event: TBD 2023-24
Initiation of phase 2 trial (USA)

Discovery

In vivo PoC

Phase 1

Phase 2

Phase 3 / pivotal

Cancer Indication: Pancreatic cancer & Multiple Myeloma
Combination with: TG01/QS-21 +/- anti-PD-1
Product candidate: Mutant KRAS¹
Next expected event: 1H 2023
First patient dosed (USA & EU)

Discovery

In vivo PoC

Phase 1

Phase 2

Phase 3 / pivotal

Two trials run and financed by collaboration partners

1Pending additional financing or partnership

Subscribe